Association between high‑density lipoproteins and prostate specific antigen: A cross‑sectional study from NHANES database

Adan,Mohamed Mohamoud; Hu,Bowen; Yan,Minbo; Hidig,Sakarie Mustafe; Dai,Yingbo; Li,Gonghui

doi:10.3892/mco.2025.2829

Association between high‑density lipoproteins and prostate specific antigen: A cross‑sectional study from NHANES database

Authors:
- Mohamed Mohamoud Adan
- Bowen Hu
- Minbo Yan
- Sakarie Mustafe Hidig
- Yingbo Dai
- Gonghui Li
View Affiliations

Affiliations: Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China, Department of Urology, The People's Hospital of Longhua, Shenzhen, Guangdong 518000, P.R. China, Department of Urology, The Fifth Affiliated Hospital of Sun Yat‑sen University, Zhuhai, Guangdong 519000, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, The fourth affiliated hospital of Zhejiang University, Yiwu, Zhejiang 322000, P.R. China, Department of Urology, The Fifth Affiliated Hospital of Sun Yat‑sen University, Zhuhai, Guangdong 519000, P.R. China, Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China
Published online on: February 18, 2025 https://doi.org/10.3892/mco.2025.2829
Article Number: 34

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

According to increasing evidence, high‑density lipoproteins (HDLs) may raise prostate‑specific antigen (PSA) levels in the prostate. The link between HDL‑cholesterol (C) and PSA, on the other hand, is debatable and challenging. Hence, the present study examined the relationship between HDL‑C and PSA in men using the National Health and Nutrition Examination Survey (NHANES) database. NHANES data were extracted for five cycles from 2001 to 2010. The data used for analysis included PSA concentrations, sociodemographic and laboratory data. After the screening, 6,669 out of 52,195 participants were included in the present study. Participants were divided into four groups based on HDL‑C quartiles. Categorical and continuous variables using weighted chi‑square tests and linear regression models were analysed to compare differences between groups. A total of three weighted multivariate linear regression models were constructed and the association between HDL‑C and PSA using a smoothed curve fit was assessed. In the present study, unadjusted and adjusted multivariate linear regression models revealed a significant positive association between PSA concentrations and serum HDL‑C levels. Specifically, each unit increase in HDL‑C ratio was associated with an increase in PSA concentration by 0.470 ng/ml (P<0.001) in the unadjusted model. In minimally adjusted models, accounting for socioeconomic and demographic factors, this association remained significant, with an increase of 0.408 ng/ml per unit increase in serum HDL‑C (P<0.001). Furthermore, the stratified analysis revealed various impacts based on socioeconomic status and HDL‑C levels, with a significant interaction between household income and HDL‑C levels (P=0.037). Exclusion of subjects with low HDL‑C levels strengthened the association, revealing a significant increase in PSA concentration with higher HDL‑C levels (0.50 ng/ml per 1 mmol/l increase, P=0.009). The findings of the present study suggest a nuanced relationship between HDL‑C levels, socioeconomic factors, and PSA concentrations, highlighting the potential importance of considering these factors in prostate cancer (Pca) screening and risk assessment. The present study found a positive association between serum HDL‑C and PSA concentrations in adult men in the United States without a Pca diagnosis.

View Figures

View References

1	Wang L, Lu B, He M, Wang Y, Wang Z and Du L: Prostate cancer incidence and mortality: Global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 10(811044)2022.PubMed/NCBI View Article : Google Scholar
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
3	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.PubMed/NCBI View Article : Google Scholar
4	Grubb RL III: Prostate cancer: Update on early detection and new biomarkers. Mo Med. 115:132–134. 2018.PubMed/NCBI
5	Narain TA and Sooriakumaran P: Beyond prostate specific antigen: New prostate cancer screening options. World J Mens Health. 40:66–73. 2022.PubMed/NCBI View Article : Google Scholar
6	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, et al: Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 384:2027–2035. 2014.PubMed/NCBI View Article : Google Scholar
7	Carlsson SV and Vickers AJ: Screening for prostate cancer. Med Clin North Am. 104:1051–1062. 2020.PubMed/NCBI View Article : Google Scholar
8	Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, et al: A multi-institutional prospective trial in the USA Confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 68:464–470. 2015.PubMed/NCBI View Article : Google Scholar
9	Buddingh KT, Maatje MGF, Putter H, Kropman RF and Pelger RCM: Do antibiotics decrease prostate-specific antigen levels and reduce the need for prostate biopsy in type IV prostatitis? A systematic literature review. Can Urol Assoc J. 12:E25–E30. 2018.PubMed/NCBI View Article : Google Scholar
10	Stattin P, Carlsson S, Holmstrom B, Vickers A, Hugosson J, Lilja H and Jonsson H: Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst. 106(dju007)2014.PubMed/NCBI View Article : Google Scholar
11	Tall AR: Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 263:256–273. 2008.PubMed/NCBI View Article : Google Scholar
12	Murtola TJ, Syvälä H, Pennanen P, Bläuer M, Solakivi T, Ylikomi T and Tammela TL: The importance of LDL and Cholesterol metabolism for prostate epithelial cell growth. PLoS One. 7(e39445)2012.PubMed/NCBI View Article : Google Scholar
13	Platz EA, Clinton SK and Giovannucci E: Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer. 123:1693–1698. 2008.PubMed/NCBI View Article : Google Scholar
14	Mondul AM, Clipp SL, Helzlsouer KJ and Platz EA: Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 21:61–68. 2010.PubMed/NCBI View Article : Google Scholar
15	https://www.cdc.gov/nchs/nhanes/index.htm.
16	Mondul AM, Weinstein SJ, Virtamo J and Albanes D: Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 22:1545–1552. 2011.PubMed/NCBI View Article : Google Scholar
17	Zhao R, Cheng G, Wang B, Qin C, Liu Y, Pan Y, Wang J, Hua L, Zhu W and Wang Z: BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. Oncotarget. 8:66051–66060. 2017.PubMed/NCBI View Article : Google Scholar
18	Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC and Giovannucci E: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 98:1819–1825. 2006.PubMed/NCBI View Article : Google Scholar
19	Mørland JG, Magnus P, Vollset SE, Leon DA, Selmer R and Tverdal A: Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20-79 years. Int J Epidemiol. 52:1257–1267. 2023.PubMed/NCBI View Article : Google Scholar
20	Ioannidou A, Watts EL, Perez-Cornago A, Platz EA, Mills IG, Key TJ and Travis RC: PRACTICAL consortium, CRUK BPC3, et al. The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study. PLoS Med. 19(e1003859)2022.PubMed/NCBI View Article : Google Scholar
21	Senapati D, Sharma V, Rath SK, Rai U and Panigrahi N: Functional implications and therapeutic targeting of androgen response elements in prostate cancer. Biochimie. 214(Pt B):188–198. 2023.PubMed/NCBI View Article : Google Scholar
22	Baio R, Napodano G, Caruana C, Molisso G, Di Mauro U, Intilla O, Pane U, D'Angelo C, Francavilla AB, Guarnaccia C, et al: Association between obesity and frequency of high-grade prostate cancer on biopsy in men: A single-center retrospective study. Mol Clin Oncol. 17(127)2022.PubMed/NCBI View Article : Google Scholar
23	Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freeman MR and Freedland SJ: Serum cholesterol and risk of high-grade prostate cancer: Results from the REDUCE study. Prostate Cancer Prostatic Dis. 21:252–259. 2018.PubMed/NCBI View Article : Google Scholar
24	Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N and Lambe M: Prostate cancer risk in the Swedish AMORIS study The interplay among triglycerides, total cholesterol, and glucose. Cancer. 117:2086–2095. 2011.PubMed/NCBI View Article : Google Scholar
25	Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K and Remaley AT: High-density lipoprotein and prostate cancer: An overview. J Epidemiol. 23:313–319. 2013.PubMed/NCBI View Article : Google Scholar
26	Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, Hayday A, Lambe M and Holmberg L: Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 22:1011–1019. 2011.PubMed/NCBI View Article : Google Scholar
27	Albertsen PC: Prostate cancer screening and treatment: Where have we come from and where are we going? BJU Int. 126:218–224. 2020.PubMed/NCBI View Article : Google Scholar